Torsdag 14 Augusti | 10:24:17 Europe / Stockholm
Svenska | English

Newbury Pharmaceuticals

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Est. tid*
2026-01-14 N/A Årsstämma
2026-01-14 08:00 Kvartalsrapport 2026-Q1
2025-10-29 11:20 Bokslutskommuniké 2025
2025-07-09 - Kvartalsrapport 2025-Q3
2025-04-09 - Kvartalsrapport 2025-Q2
2025-01-24 - Kvartalsrapport 2025-Q1
2025-01-16 - X-dag ordinarie utdelning NEWBRY 0.00 SEK
2025-01-15 - Årsstämma
2024-10-23 - Bokslutskommuniké 2024
2024-07-31 - Extra Bolagsstämma 2024
2024-07-10 - Kvartalsrapport 2024-Q3
2024-04-10 - Kvartalsrapport 2024-Q2
2024-01-11 - X-dag ordinarie utdelning NEWBRY 0.00 SEK
2024-01-10 - Årsstämma
2024-01-10 - Kvartalsrapport 2024-Q1
2023-10-11 - Bokslutskommuniké 2023
2023-07-14 - Kvartalsrapport 2023-Q3
2023-04-12 - Kvartalsrapport 2023-Q2
2023-01-12 - X-dag ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11 - Årsstämma
2023-01-11 - Kvartalsrapport 2023-Q1
2022-10-13 - Bokslutskommuniké 2022
2022-07-06 - Kvartalsrapport 2022-Q3
2022-04-13 - Kvartalsrapport 2022-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades 2020 och har sitt huvudkontor i Lund.
Newbury Pharmaceuticals Secures Generic Approval for Melatonin Newbury
2025-08-11 10:00:00

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Melatonin Newbury 2 mg prolonged-release tablets in Finland as the first country in a Nordic registration procedure. Approvals in Sweden, Norway and Denmark are expected to follow upon finalized national reviews.

Melatonin Newbury is indicated as monotherapy for the short-term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over. Melatonin Newbury is a generic version of Circadin. The current annual value of the Nordic market is estimated to be 11 MEUR according to DLMI Nordic Pharma Insights. 

“The successful approval of Melatonin Newbury highlights Newbury's capability to offer a diverse and comprehensive portfolio and it is also Newbury’s second marketing authorization in Finland” says Mr Lars Minor CEO of Newbury

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

Newbury Pharmaceuticals Secures Generic Approval for Melatonin Newbury

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden